A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2018
Price : $35 *
At a glance
- Drugs TAK 233 (Primary)
- Indications Stress incontinence
- Focus Pharmacodynamics
- Sponsors Takeda
- 27 Oct 2014 Last checked against ClinicalTrials.gov.
- 20 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2014 New trial record